Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX Followed by HAI Floxuridine-Dexamethasone and Systemic mFOLFIRI in Unresectable Intrahepatic Cholangiocarcinoma
NCT04251715Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine in intrahepatic cholangiocarcinoma (ICC), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Frequency of Abnormal Liver Function at 6 months and Disease Control Rate During HAI+SYS at 6 months. Started Apr 2021; status: terminated.
02
Drugs
floxuridine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04251715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251715.